Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients across prior historical exacerbation subgroups in the phase 3 LIBERTY ASTHMA QUEST study

被引：0
|
作者：
Ford, L. [1 ]
Corren, J. [2 ]
Kuna, P. [3 ]
Dong, Q. [4 ]
Staudinger, H. [5 ]
Maroni, J. [6 ]
Rowe, P. [5 ]
Amin, N. [6 ]
Pirozzi, G. [5 ]
Ruddy, M. [6 ]
Akinlade, B. [6 ]
Graham, N. M. H. [6 ]
Teper, A. [5 ]
机构：
[1] Ctr Asthma & Allergy, Bellevue, WA USA
[2] Ronald Reagan UCLA Med Ctr, Santa Monica, CA USA
[3] Med Univ Lodz, Lodz, Poland
[4] Sanofi Genzyme, Cambridge, England
[5] Sanofi, Bridgewater, MA USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
0854
引用
收藏
页码：464 / 465
页数：2
相关论文
共 50 条
  • [31] Dupilumab Provides Rapid and Sustained Exacerbation Protection in Patients with Uncontrolled, Moderate-to-Severe Type 2 Inflammatory Asthma Enrolled in the LIBERTY ASTHMA QUEST Study
    Corren, J.
    Rogers, L.
    Papi, A.
    Chen, Z.
    Pandit-Abid, N.
    Rowe, P.
    Deniz, Y.
    Ortiz, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [32] Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations
    Hamelmann, Eckard
    Deschildre, Antoine
    Ducharme, Francine M.
    Sher, Lawrence D.
    De Mir, Ines
    Xia, Changming
    Gall, Rebecca
    Ledanois, Olivier
    Jacob-Nara, Juby A.
    Sacks, Harry
    Rowe, Paul J.
    Deniz, Yamo
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [33] Dupilumab improved lung function and reduced exacerbation rates in patients with moderate-tosevere asthma and prior exacerbations: LIBERTY ASTHMA TRAVERSE study
    Rhee, Chin Kook
    Corren, Jonathan
    Castro, Mario
    Maspero, Jorge F.
    Humbert, Marc
    Halpin, David M. G.
    Altincatal, Arman
    Pandit-Abid, Nami
    Soler, Xavier
    Siddiqui, Shahid
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    RESPIROLOGY, 2023, 28 : 76 - 78
  • [34] Dupilumab Reduces Exacerbations And Improves Lung Function Regardless Of Prior Asthma Exacerbation Status: LIBERTY ASTHMA TRAVERSE Open-Label Extension Study
    Papi, Alberto
    Castro, Mario
    Busse, William
    Korn, Stephanie
    Xia, Changming
    Soler, Xavier
    Pandit-Abid, Nami
    Radwan, Amr
    Jacob-Nara, Juby
    Rowe, Paul
    Deniz, Yamo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB193 - AB193
  • [35] DUPILUMAB IMPROVES QUALITY OF LIFE IN CAREGIVERS OF CHILDREN WITH UNCONTROLLED MODERATE-TO-SEVERE ASTHMA: LIBERTY ASTHMA VOYAGE STUDY
    Fiocchi, A. G.
    Phipatanakul, W.
    Durrani, S.
    Cole, J.
    Msihid, J.
    Lederer, D. J.
    Hardin, M.
    Zhang, Y.
    Khan, A. H.
    VALUE IN HEALTH, 2022, 25 (07) : S294 - S295
  • [36] Dupilumab Improves Quality of Life in Caregivers of Children with Uncontrolled Moderate-to-severe Asthma: LIBERTY ASTHMA VOYAGE Study
    Fiocchi, Alessandro G.
    Phipatanakul, Wanda
    Durrani, Sandy R.
    Cole, Jeremy
    Liu, Dongfang
    Msihid, Jerome
    Lederer, David J.
    Hardin, Megan
    Zhang, Yi
    Khan, Asif H.
    PEDIATRICS, 2022, 149 (01)
  • [37] Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study
    Busse, William
    Pavord, Ian
    Wenzel, Sally
    Bateman, Eric
    Casale, Thomas
    FitzGerald, J.
    Rice, Megan
    Deniz, Yamo
    Patel, Naimish
    Harel, Sivan
    Rowe, Paul
    Graham, Neil
    O'Riordan, Thomas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB21 - AB21
  • [38] Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study
    Tohda, Yuji
    Nakamura, Yoichi
    Fujisawa, Takao
    Ebisawa, Motohiro
    Msihid, Jerome
    Djandji, Michel
    Ortiz, Benjamin
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Ishida, Masato
    Arima, Kazuhiko
    ALLERGOLOGY INTERNATIONAL, 2023, 72 (01) : 89 - 99
  • [39] FeNO as a Potential Prognostic and Predictive Marker of Lung Function Decline in Patients with Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA QUEST
    Pavord, I. D.
    Brusselle, G.
    Jackson, D. J.
    Brightling, C. E.
    Papi, A.
    Maspero, J. F.
    Rabe, K. F.
    Korn, S.
    Zhang, M.
    Djandji, M.
    Hardin, M.
    Gomez, L. De Prado
    Jacob-Nara, J. A.
    Rowe, P. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [40] DUPILUMAB REDUCES SYSTEMIC CORTICOSTEROID USE IN CHILDREN WITH UNCONTROLLED MODERATE-TO-SEVERE ASTHMA REGARDLESS OF PRIOR EXACERBATION HISTORY
    Ducharme, F. M.
    Sher, L. D.
    Hamelmann, E.
    de Mir, I
    Xia, C.
    Gall, R.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Ledanois, O.
    Deniz, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S477 - S477
12345